Low miR-145 expression level is associated with poor pathological differentiation and poor prognosis in non-small cell lung cancer

Biomedicine and Pharmacotherapy

Volumn 69, Issue , 2015, Pages 301-305

  Shen, Hua ^a,c   Shen, Jianxin ^b   Wang, Lin ^c,d   Shi, Zhumei ^c,d   Wang, Min ^c,d   Jiang, Bing hua ^c,d   Shu, Yongqian ^a,c  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b HEBEI NORTH UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d Nanjing Ninggao Individual Medical Technology Innovation Center Ltd   (China)

Author keywords

MiR 145; NSCLC; Pathological differentiation; Prognosis

Indexed keywords

MICRORNA 145; MICRORNA; MIRN145 MICRORNA, HUMAN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE MARKER; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; LUNG ADENOCARCINOMA; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL LUNG CARCINOMA; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; DISEASE-FREE SURVIVAL; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MICRORNAS;

EID: 84922260024     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.12.019     Document Type: Article

References (26)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350:351-360.
3. Kato H., Ichinose Y., Ohta M., Hata E., Tsubota N., Tada H., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004, 350:1713-1721.
4. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005, 352:2589-2597.
5. Douillard J.Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzales-Larriba J.L., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006, 7:719-727.
6. Galluzzi L., Senovilla L., Vitale I., Michels J., Martins I., Kepp O., et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012, 31:1869-1883.
7. Barroso-delJesus A., Romero-Lopez C., Lucena-Aguilar G., Melen G.J., Sanchez L., Ligero G., et al. Embryonic stem cell-specific miR302-367 cluster: human gene structure and functional characterization of its core promoter. Mol Cell Biol 2008, 28:6609-6619.
8. Shen H., Liu J., Wang R., Qian X., Xu R., Xu T., et al. Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression. Biomed Pharmacother 2014, 68:307-313.
9. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006.
10. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518.
11. Wei J., Gao W., Zhu C.J., Liu Y.Q., Mei Z., Cheng T., et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer 2011, 30:407-414.
12. Wei J., Liu L.K., Gao W., Zhu C.J., Liu Y.Q., Cheng T., et al. Reduction of plasma microRNA-21 is associated with chemotherapeutic response in patients with non-small cell lung cancer. Chin J Cancer Res 2011, 23:123-128.
13. Valeri N., Gasparini P., Braconi C., Paone A., Lovat F., Fabbri M., et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A 2010, 107:21098-21103.
14. Wang X. A PCR-based platform for microRNA expression profiling studies. RNA 2009, 15:716-723.
15. Hua S., Xiaotao X., Renhua G., Yongmei Y., Lianke L., Wen G., et al. Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells. Biomed Pharmacother 2012, 66:89-97.
16. Markou A., Sourvinou I., Vorkas P.A., Yousef G.M., Lianidou E. Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer 2013, 81:388-396.
17. Liu X., Sempere L.F., Galimberti F., Freemantle S.J., Black C., Dragnev K.H., et al. Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res 2009, 15:1177-1183.
18. Chen Z., Zeng H., Guo Y., Liu P., Pan H., Deng A., et al. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res 2010, 29:151.
19. Cho W.C., Chow A.S., Au J.S. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol 2011, 8:125-131.
20. Sachdeva M., Mo Y.Y. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 2010, 70:378-387.
21. Wu X., Xiao H. miRNAs modulate the drug response of tumor cells. Sci China C Life Sci 2009, 52:797-801.
22. Sarkar F.H., Li Y., Wang Z., Kong D., Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 2010, 13:57-66.
23. Zhao C., Xu Y., Zhang Y., Tan W., Xue J., Yang Z., et al. Downregulation of miR-145 contributes to lung adenocarcinoma cell growth to form brain metastases. Oncol Rep 2013, 30:2027-2034.
24. Campayo M., Navarro A., Vinolas N., Diaz T., Tejero R., Gimferrer J.M., et al. Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer. Eur Respir J 2013, 41:1172-1178.
25. Zhu X., Li Y., Xie C., Yin X., Liu Y., Cao Y., et al. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer 2014, 135:1286-1296.
26. Findlay V.J., Wang C., Nogueira L.M., Hurst K., Quirk D., Ethier S.P., et al. SNAI2 Modulates Colorectal Cancer 5-Fluorouracil Sensitivity through miR145 Repression. Mol Cancer Ther 2014.